<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952454</url>
  </required_header>
  <id_info>
    <org_study_id>1533-2020</org_study_id>
    <nct_id>NCT04952454</nct_id>
  </id_info>
  <brief_title>Functional Epiphora Management Via Different Dacryocystorhinostomy (DCR) Techniques</brief_title>
  <official_title>Non-endoscopic Endonasal, Transcanalicular, or External Dacryocystorhinostomy for Functional Epiphora: Which is Better?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      135 eyes of 135 patients treated between 2005 and 2017 will be included in this study. The&#xD;
      diagnosis of functional epiphora was made based on a patent lacrimal system with a delay in&#xD;
      the fluorescein dye disappearance test (FDDT) or dacryoscintigraphy (DSG) without any ocular&#xD;
      surface or eyelid abnormalities. The absence of epiphora and normalization of FDDT&#xD;
      postoperatively was defined as success. The study's hypothesis is that external DCR with a&#xD;
      suitable technique will have better results compared to endonasal and transcanalicular DCR&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who report resolution of theri tearing and normalization of fluorescein dye disappearance test.</measure>
    <time_frame>Last follow-up time, approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have continuing epiphora after the surgery with an anatomically blocked tear duct.</measure>
    <time_frame>Last follow-up time, approximately 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Functional Epiphora (Tearing Without Any Anatomical Block)</condition>
  <arm_group>
    <arm_group_label>External DCR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with External DCR for functional epiphora</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endonasal DCR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with Endonasal DCR for functional epiphora</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcanalicular DCR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with Transcanalicular DCR for functional epiphora</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>External Dacryocystorhinostomy</intervention_name>
    <description>The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via skin incision.</description>
    <arm_group_label>External DCR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endonasal Dacryocystorhinostomy</intervention_name>
    <description>The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via endonasal route.</description>
    <arm_group_label>Endonasal DCR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcanalicular Dacryocystorhinostomy</intervention_name>
    <description>The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via transcanalicular route.</description>
    <arm_group_label>Transcanalicular DCR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patent lacrimal irrigation and delay in the lacrimal transit time demonstrated by&#xD;
             fluorescein dye disappearance test (FDDT) or a dacryoscintigraphy (DSG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dry eye (tear break up time less than 10 seconds), ocular surface disorders, eyelid&#xD;
             malposition or laxity, orbicularis weakness, partial block or stenosis of the lacrimal&#xD;
             drainage, history of previous nasal, lacrimal, or ophthalmic surgeries, and a&#xD;
             postoperative follow-up time less than six months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Can Ozturker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University, Istanbul Facukty Of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyoglu Eye Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34421</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Can Ozturker</investigator_full_name>
    <investigator_title>Asist. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacrimal Apparatus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

